Anders Hovland

Anders Hovland

Auto-generated profile, based on publicly available information

Anders Hovland

Department of Medicine, Nordland Hospital, 8092 Bodø, Norway

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Atherosclerosis
Verified
Journal Article
Open access
AHAnders Hovland
Anders Hovland
LJLena Jonasson
Lena Jonasson
PGPeter Garred
Peter Garred
AYArne Yndestad
Arne Yndestad
PAPål Aukrust
Pål Aukrust
TMTom E. Mollnes
Tom E. Mollnes
Despite recent medical advances, atherosclerosis is a global burden accounting for numerous deaths and hospital admissions. Immune-mediated inflammation is a major component of the atherosclerotic process, but earlier research focus on adaptive immunity has gradually switched towards the role of innate immunity. The complement system and toll-like receptors (TLRs), and the crosstalk between them, may be of particular interest both with respect to pathogenesis and as therapeutic targets in atherosclerosis. Animal studies indicate that inhibition of C3a and C5a reduces atherosclerosis. In humans modified LDL-cholesterol activate complement and TLRs leading to downstream inflammation, and histopathological studies indicate that the innate immune system is present in atherosclerotic lesions. Moreover, clinical studies have demonstrated that both complement and TLRs are upregulated in atherosclerotic diseases, although interventional trials have this far been disappointing. However, based on recent research showing an intimate interplay between complement and TLRs we propose a model in which combined inhibition of both complement and TLRs may represent a potent anti-inflammatory therapeutic approach to reduce atherosclerosis.

1 October 2014 in Molecular Immunology
Verified
Journal Article
Closed access
KLKnut T. Lappegård
Knut T. Lappegård
PGPeter Garred
Peter Garred
LJLena Jonasson
Lena Jonasson
TETerje Espevik
Terje Espevik
PAPål Aukrust
Pål Aukrust
AHAnders Hovland
Anders Hovland

1 November 2019 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
LMLiv J. Mundal
Liv J. Mundal
AHAnders Hovland
Anders Hovland
JIJannicke Igland
Jannicke Igland
MVMarit B Veierød
Marit B Veierød
KHKirsten B. Holven
Kirsten B. Holven
KRKjetil Retterstøl
Kjetil Retterstøl
Aortic valve stenosis (AS) is the most common valvular disease in the western world. The underlying pathophysiology of AS is divided into an initiation phase resembling atherosclerosis, including lipid infiltration, oxidation, and inflammation, and a propagation phase characterized by fibrosis and calcification.1 Even if low-density lipoprotein (LDL) cholesterol may be important in the initiation phase, lipid-lowering therapy with statins and ezetimibe has been unsuccessful in halting the disease.2

1 January 2009 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
AHAnders Hovland
Anders Hovland
RHRandolf Hardersen
Randolf Hardersen
JSJoe Sexton
Joe Sexton
TMTom Eirik Mollnes
Tom Eirik Mollnes
KLKnut Tore Lappegård
Knut Tore Lappegård

18 July 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
KLKnut Tore Lappegård
Knut Tore Lappegård
CKChristian Kjellmo
Christian Kjellmo
AHAnders Hovland
Anders Hovland
High-density lipoproteins (HDL) are a heterogenous group of plasma molecules with a large variety in composition. There is a wide specter in lipid content and the number of different proteins that has been associated with HDL is approaching 100. Given this heterogeneity and the fact that the total amount of HDL is inversely related to the risk of coronary heart disease (CHD), there has been increasing interest in the function of specific HDL subgroups and in what way measuring and quantifying these subgroups could be of clinical importance in determining individual CHD risk. If certain subgroups appear to be more protective than others, it may also in the future be possible to pharmacologically increase beneficial and decrease harmful subgroups in order to reduce CHD risk. In this review we give a short historical perspective, summarize some of the recent clinical findings regarding HDL subclassifications and discuss why such classification may or may not be of clinical relevance.

5 June 2012 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
AHA. Hovland
A. Hovland
KLK. T. Lappegård
K. T. Lappegård
TMT. E. Mollnes
T. E. Mollnes
Low‐density lipoprotein (LDL) apheresis is an extracorporeal treatment modality used in high‐risk patients when LDL cholesterol levels cannot be reduced adequately with medication. The treatment is highly effective, but could be affected by potential unwanted effects on pro‐ and anti‐inflammatory biomarkers. In this paper, we review the literature regarding the effect of LDL apheresis on pro‐ and anti‐inflammatory biomarkers important in atherosclerosis, also as patients in LDL apheresis have high risk for atherosclerotic complications. We discuss the effect of LDL apheresis on complement, cytokines and finally a group of other selected pro‐ and anti‐inflammatory biomarkers. The complement system is affected by LDL apheresis, and there are differences between different LDL apheresis systems. The plasma separation columns seem to trigger the formation of proinflammatory complement factors including C3a and C5a, while the same anaphylatoxins are adsorbed by the LDL apheresis columns, however, to varying degree. Proinflammatory cytokines are to some extent adsorbed by the LDL apheresis columns, while some of the anti‐inflammatory cytokines increase during treatment. Finally, we discuss the effect of apheresis on different biomarkers including C‐reactive protein, fibrinogen, adhesion molecules, myeloperoxidase and HDL cholesterol. In conclusion, even if there are differences between pro‐ and anti‐inflammatory biomarkers during LDL apheresis, the consequences for the patients are largely unknown and larger studies need to be performed. Preferably, they should be comparing the effect of different LDL apheresis columns on the total inflammatory profile, and this should be related to clinical endpoints.